Angina Drug Approved

APRIL 01, 2006
Susan Farley

The FDA recently approved ranolazine extended-release tablets (Ranexa) for the treatment of angina, making it the first new pharmaceutical option for the treatment of angina in >20 years. According to a statement from the manufacturer, CV Therapeutics Inc, ranolazine prolongs the QT interval and therefore should be used in patients who have not achieved an adequate response with other antianginal drugs. Ranolazine should be used in combination with amlodipine, betablockers, or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than in men. CV Therapeutics expects to have Ranexa available to pharmacies later this spring.

Ms. Farley is a freelance medical writer based in Wakefield, RI.




SHARE THIS SHARE THIS
0

Become A RESPIMAT T.O.P. Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?


Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.